Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LPCN
  • CUSIP: N/A
  • Web: www.lipocine.com
Capitalization:
  • Market Cap: $82.12 million
  • Outstanding Shares: 20,673,000
Average Prices:
  • 50 Day Moving Avg: $3.99
  • 200 Day Moving Avg: $4.04
  • 52 Week Range: $3.03 - $5.33
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.54
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.22 per share
  • Price / Book: 3.27
Profitability:
  • EBITDA: ($16,590,000.00)
  • Return on Equity: -64.49%
  • Return on Assets: -59.80%
Debt:
  • Current Ratio: 9.66%
  • Quick Ratio: 9.66%
Misc:
  • Average Volume: 204,141 shs.
  • Beta: 2.02
  • Short Ratio: 6.01
 

Frequently Asked Questions for Lipocine (NASDAQ:LPCN)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. View Lipocine's Earnings History.

When will Lipocine make its next earnings announcement?

Lipocine is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Lipocine.

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?

3 brokers have issued twelve-month price targets for Lipocine's shares. Their predictions range from $11.00 to $38.00. On average, they anticipate Lipocine's share price to reach $24.67 in the next year. View Analyst Ratings for Lipocine.

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:

  • Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
  • Gregory Bass, Executive Vice President, Chief Commercial Officer
  • Stephen Anthony Hill M.D., Lead Independent Director
  • Jeffrey A. Fink, Director
  • Richard Dana Ono, Director
  • John W. Higuchi, Non-Executive Director

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of Lipocine stock can currently be purchased for approximately $3.99.


MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.67 (518.21% upside)
Consensus Price Target History for Lipocine (NASDAQ:LPCN)
Price Target History for Lipocine (NASDAQ:LPCN)
Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Roth CapitalSet Price TargetBuy$38.00MediumView Rating Details
8/7/2017Canaccord GenuitySet Price TargetBuy$11.00LowView Rating Details
4/26/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
Earnings by Quarter for Lipocine (NASDAQ:LPCN)
Earnings History by Quarter for Lipocine (NASDAQ LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
8/7/2017Q2 2017($0.30)($0.31)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20172($0.33)($0.31)($0.32)
Q3 20172($0.28)($0.12)($0.20)
Q4 20172($0.30)($0.15)($0.23)
Q1 20181$0.82$0.82$0.82
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 26.39%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
Source:
DateHeadline
streetinsider.com logoLipocine (LPCN) Says FDA Advisory Committee is Scheduled to Review TLANDO on January 10 - StreetInsider.com
www.streetinsider.com - October 18 at 3:26 PM
finance.yahoo.com logoFDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018
finance.yahoo.com - October 18 at 3:26 PM
seekingalpha.com logoLipocine: Playing The PDUFA Runup - Seeking Alpha
seekingalpha.com - October 15 at 7:21 PM
americanbankingnews.com logoAnalyzing Lipocine (LPCN) & Its Competitors
www.americanbankingnews.com - October 15 at 6:26 AM
prnewswire.com logoStocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine - PR Newswire (press release)
www.prnewswire.com - September 26 at 5:52 PM
bizjournals.com logoStocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine
www.bizjournals.com - September 26 at 9:27 AM
finance.yahoo.com logoLPCN: Advisory Committee Required and USPTO Issues Motion for Tlando
finance.yahoo.com - September 23 at 6:08 AM
rttnews.com logoFDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ
www.rttnews.com - September 22 at 11:06 AM
streetinsider.com logoLipocine (LPCN) Announces FDA Advisory Committee Meeting for TLANDO - StreetInsider.com
www.streetinsider.com - September 21 at 4:20 PM
globenewswire.com logoLipocine Announces Motions Decision by USPTO in Interference Against Clarus - GlobeNewswire (press release)
globenewswire.com - September 21 at 4:20 PM
finance.yahoo.com logoLipocine Announces FDA Advisory Committee Meeting for TLANDO™
finance.yahoo.com - September 21 at 4:20 PM
finance.yahoo.com logoLipocine Announces Motions Decision by USPTO in Interference Against Clarus
finance.yahoo.com - September 21 at 4:20 PM
finance.yahoo.com logoLipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 2:51 AM
seekingalpha.com logoLipocine (LPCN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 7:20 AM
finance.yahoo.com logoLipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 4:13 PM
americanbankingnews.com logoLipocine Inc. (LPCN) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - August 28 at 10:28 AM
bizjournals.com logoDaily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma
www.bizjournals.com - August 24 at 8:49 AM
nasdaq.com logoLipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date,
www.nasdaq.com - August 15 at 1:09 AM
finance.yahoo.com logoLipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018
finance.yahoo.com - August 15 at 1:09 AM
finance.yahoo.com logoLPCN: Second Quarter Operational and Financial Results
finance.yahoo.com - August 15 at 1:09 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: August 12, 2017
seekingalpha.com - August 12 at 7:30 PM
nasdaq.com logoLipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism - Nasdaq
www.nasdaq.com - August 10 at 3:07 AM
finance.yahoo.com logoLipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
finance.yahoo.com - August 10 at 3:07 AM
americanbankingnews.com logoLipocine Inc. (LPCN) Issues Earnings Results
www.americanbankingnews.com - August 8 at 1:36 PM
reuters.com logoBRIEF-Lipocine posts Q2 loss per share $0.31
www.reuters.com - August 7 at 8:54 PM
americanbankingnews.com logoLipocine Inc. (LPCN) PT Set at $11.00 by Canaccord Genuity
www.americanbankingnews.com - August 7 at 6:20 PM
globenewswire.com logoLipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 - GlobeNewswire (press release)
globenewswire.com - August 7 at 3:52 PM
finance.yahoo.com logoLipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017
finance.yahoo.com - August 7 at 3:52 PM
finance.yahoo.com logoLipocine reports 2Q loss
finance.yahoo.com - August 7 at 3:52 PM
finance.yahoo.com logoLipocine to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 3:30 AM
americanbankingnews.com logo-$0.33 Earnings Per Share Expected for Lipocine Inc. (NASDAQ:LPCN) This Quarter
www.americanbankingnews.com - July 20 at 8:20 PM
reuters.com logoBRIEF-Lipocine announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth
www.reuters.com - June 27 at 5:23 AM
streetinsider.com logoLipocine (LPCN) Submission of Special Protocol Assessment on LPCN 1107 to FDA
www.streetinsider.com - June 27 at 5:23 AM
nasdaq.com logoLipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth - Nasdaq
www.nasdaq.com - June 27 at 12:23 AM
benzinga.com logoLicopine Pops And Drops After LPCN 1021 Meets Primary Endpoint - Benzinga
www.benzinga.com - June 22 at 8:57 AM
benzinga.com logoLipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint
www.benzinga.com - June 20 at 7:18 PM
streetinsider.com logoLipocine (LPCN) Announced Results from Dosing Validation and Dosing Flexibility Studies Evaluating Efficacy and Tolerability of LPCN 1021
www.streetinsider.com - June 20 at 7:18 PM
rttnews.com logoAMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade
www.rttnews.com - June 20 at 3:25 AM
nasdaq.com logoLipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation
www.nasdaq.com - June 19 at 10:24 PM
streetinsider.com logoAfter-Hours Stock Movers 06/19: (LPCN) (ENPH) (TSLA) Higher; (RS) (CMG) (CLVS) Lower (more...)
www.streetinsider.com - June 19 at 10:24 PM
reuters.com logoBRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021
www.reuters.com - June 19 at 10:24 PM
globenewswire.com logoLipocine to Host Conference Call and Webcast to Discuss Top-Line ... - GlobeNewswire (press release)
globenewswire.com - June 19 at 5:22 PM
seekingalpha.com logoThe Future Of Lipocine's Lead Product Candidate, LPCN1021
seekingalpha.com - June 8 at 7:19 PM
globenewswire.com logoLipocine to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 3 at 8:17 AM
businesswire.com logoRobbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - May 11 at 11:52 PM
globenewswire.com logoLipocine Announces Financial and Operational Results for the First Quarter 2017 - GlobeNewswire (press release)
globenewswire.com - May 8 at 5:57 PM
marketbeat.com logoLipocine reports 1Q loss
marketbeat.com - May 8 at 8:15 AM
streetinsider.com logoLipocine (LPCN) Says Enrollment in LPCN 1021 Fixed Dose Trials Has Been Completed
www.streetinsider.com - April 24 at 4:58 PM
globenewswire.com logoLipocine to Present at 16th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 28 at 10:57 PM
globenewswire.com logoLipocine to Present at 27th Annual Oppenheimer Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 11:37 PM

Social

Chart

Lipocine (LPCN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.